LPCN logo

LPCN Lipocine Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$1.48
-0.02 (-1.33%)

Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost inve…

Market Cap: $16.39Mwww.lipocine.com

Price

No data yet.

Social Signal Score

52
5d
—
30d
50
1 mentions
—
60d
50
3 mentions
—
90d
55
5 mentions
—
news: 5

Analyst Ratings

9 analysts
Buyconsensus
Strong Buy 0Buy 7Hold 2Sell 0Strong Sell 0
Avg price target$4+170.3%
Low $4Median $4High $4
Current Consensus

Revenue

$2.29M
$-3.12M$3.28M$9.68M$16.09M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-1.97
$-2.16–$-1.77
1 analysts
FY2026
$-1.37
$-1.51–$-1.23
1 analysts
FY2027
$-1.22
$-1.33–$-1.10
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Mahesh V. Patel
Sector
Healthcare
Industry
Biotechnology
Employees
14
Beta
0.50
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
-8.30
www.lipocine.com